Loading company
Eledon Pharmaceuticals, Inc.
ELDN · Nasdaq · Healthcare · Biotechnology
$2.52-5.1%Sep 29 close
- 1M
- -16.4%
- 6M
- -16.2%
- 1Y
- -5.5%
- 5Y
- -60.8%
ELDN · Nasdaq · Healthcare · Biotechnology
$2.52-5.1%Sep 29 close
The quarter ending March 31, 2017, against the same quarter a year earlier.
| Measure | 3 months toMar 31, 2017 | 3 months toMar 31, 2016 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$31.6M | -$11.2M | -182.01% |
| Profit per share | -$0.27 | -$0.13 | -107.69% |
| Free Cash Flow | -$1.3M | -$9.1M | +85.93% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Eledon Pharmaceuticals, Inc. has no earnings call transcript available.
“During the first half of the year, we made meaningful progress establishing the regulatory framework for our planned Phase 3 kidney transplantation program, which we expect to initiate later this year,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Pharmaceuticals and tegoprubart Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40L biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Eledon Pharmaceuticals, Inc.’s Item 2.02 8-K filed August 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.